

Research article

Open Access

Mutational analysis of molecular requirements for the actions of general anaesthetics at the γ -aminobutyric acid_A receptor subtype, $\alpha 1\beta 2\gamma 2$

Roberta Siegwart[†], Karin Krähenbühl[†], Sachar Lambert and Uwe Rudolph*

Address: Institute of Pharmacology and Toxicology, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland

Email: Roberta Siegwart - siegwart@transelec.ch; Karin Krähenbühl - karinkraehenbuhl@yahoo.com; Sachar Lambert - sachar@pharma.unizh.ch; Uwe Rudolph* - rudolph@pharma.unizh.ch

* Corresponding author †Equal contributors

Published: 12 November 2003

Received: 02 September 2003

BMC Pharmacology 2003, 3:13

Accepted: 12 November 2003

This article is available from: <http://www.biomedcentral.com/1471-2210/3/13>

© 2003 Siegwart et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background: Amino acids in the β subunit contribute to the action of general anaesthetics on GABA_A receptors. We have now characterized the phenotypic effect of two β subunit mutations in the most abundant GABA_A receptor subtype, $\alpha 1\beta 2\gamma 2$.

Results: The $\beta 2(N265M)$ mutation in M2 decreased the modulatory actions of propofol, etomidate and enflurane, but not of alphaxalone, while the direct actions of propofol, etomidate and alphaxalone were impaired. The $\beta 2(M286W)$ mutation in M3 decreased the modulatory actions of propofol, etomidate and enflurane, but not of alphaxalone, whereas the direct action of propofol and etomidate, but not of alphaxalone, was impaired.

Conclusions: We found that the actions of general anaesthetics at $\alpha 1\beta 2(N265M)\gamma 2$ and $\alpha 1\beta 2(M286W)\gamma 2$ GABA_A receptors are similar to those previously observed at $\alpha 2\beta 3(N265M)\gamma 2$ and $\alpha 2\beta 3(M286W)\gamma 2$ GABA_A receptors, respectively, with the notable exceptions that the direct action of propofol was decreased in $\alpha 1\beta 2(M286W)\gamma 2$ receptors but indistinguishable from wild type in $\alpha 2\beta 3(M286W)\gamma 2$ receptors and that the direct action of alphaxalone was decreased in $\alpha 1\beta 2(N265M)\gamma 2$ but not $\alpha 2\beta 3(N265M)\gamma 2$ receptors and indistinguishable from wild type in $\alpha 1\beta 2(M286W)\gamma 2$ receptors but increased in $\alpha 2\beta 3(M286W)\gamma 2$ receptors. Thus, selected phenotypic consequences of these two mutations are GABA_A receptor subtype-specific.

Background

General anaesthetics are among the medically most widely used and important drugs. However, their mechanism of action is still poorly understood. They modulate the activity of ligand-gated ion channels (for review see [1,2]). In particular, at surgical concentrations, most general anaesthetics potentiate GABA_A receptor-mediated responses. Amino acids have been identified in the second and third transmembrane regions (TM2 and TM3) of α and β subunits which appear to be necessary for the action

of general anaesthetics on the GABA_A receptor. These include in TM2 an asparagine at position 265 of the $\beta 3$ subunit and in TM3 a methionine at position 286 in $\beta 1$ or $\beta 3$ [3–6]. Most electrophysiological studies have been performed using $\alpha\beta$ subunit combinations, whereas most GABA_A receptors in the central nervous system apparently consist of α , β and γ subunits. The presence of a γ subunit may alter the effects of a mutation at these residues [7]. Moreover, various combinations of α and β subunits might also confer distinct properties on the respective




Figure 1
GABA dose-response curves for wild-type and point-mutated $\alpha 1\beta 2\gamma 2$ GABA_A receptors transiently expressed in HEK 293 cells. The data points and error bars represent the means and standard errors for the different GABA concentrations (n = 8).

receptors. In particular, it is not known which functional consequences a mutation in the TM2 or TM3 region of the β subunit would have on the by far most abundant GABA_A receptor subtype in the CNS, $\alpha 1\beta 2\gamma 2$, which represents ca. 50% of all GABA_A receptors [8]. The $\alpha 1\beta 2\gamma 2$ GABA_A receptor is an interesting candidate for mediating anaesthetic responses *in vivo*. We therefore investigated the pharmacological properties of recombinant $\alpha 1\beta 2\gamma 2$ receptors carrying the $\beta 2$ (N265M) and $\beta 2$ (M286W) mutations to assess their suitability as potential knock-in point mutations in mice.

Results

GABA-sensitivity of wild-type and point-mutated recombinant $\alpha 1\beta 2\gamma 2$ GABA_A receptors

To determine the relevance of the amino acids N265 and M286 in the GABA_A receptor $\beta 2$ subunit for the action of general anaesthetics on the $\alpha 1\beta 2\gamma 2$ GABA_A receptor, we introduced the point mutations $\beta 2$ (N265M) and $\beta 2$ (M286W) by site directed mutagenesis. Wild-type and mutant $\beta 2$ subunits were coexpressed with $\alpha 1$ and $\gamma 2$ subunits in HEK 293 cells.

The GABA EC₅₀ value for the $\alpha 1\beta 2\gamma 2$ receptor was 5.9 ± 0.5 μM (n = 8), in line with previously published reports (4.5–20 μM) [9–12] (Fig. 1). The presence of the $\gamma 2$ subunit in the receptor complex was confirmed by the observation that 1 μM diazepam potentiate the current evoked by 32 μM GABA by 277 ± 48.2 % (not shown). The GABA dose-response curve for the $\alpha 1\beta 2$ (N265M) $\gamma 2$ receptor was shifted to the right with an EC₅₀ of 20 ± 2.2 μM (n = 8)

which was significantly higher than the EC₅₀ of the $\alpha 1\beta 2\gamma 2$ receptor (5.9 ± 0.5 μM (n = 8); p < 0.05) (Fig. 1). In contrast, the GABA dose-response curve for the $\alpha 1\beta 2$ (M286W) $\gamma 2$ receptor was shifted to the left with an EC₅₀ of 1.9 ± 0.15 μM (n = 8) significantly smaller compared to wild type (p < 0.05) (Fig. 1). The Hill coefficient was not significantly altered by the two mutations ($\alpha 1\beta 2\gamma 2$: Hill = 1.4 ± 0.15; $\alpha 1\beta 2$ (N265M) $\gamma 2$: Hill = 1.4 ± 0.2; $\alpha 1\beta 2$ (M286W) $\gamma 2$: Hill = 1.5 ± 0.2). The I_{max} values for all receptor combinations were not significantly different ($\alpha 1\beta 2\gamma 2$: I_{max} = 1269 ± 524 pA; $\alpha 1\beta 2$ (N265M) $\gamma 2$: I_{max} = 1944 ± 562 pA (p > 0.05); $\alpha 1\beta 2$ (M286W) $\gamma 2$: I_{max} = 1947 ± 646 pA (p > 0.05)). Thus, whereas the N265M mutation decreased the sensitivity to GABA, the M286W mutation led to an increase in the sensitivity to GABA.

Modulation of GABA-induced currents by general anaesthetics

To test the modulatory activity of anaesthetics, GABA concentrations corresponding to the EC₁₅ were used ($\alpha 1\beta 2\gamma 2$: 3 μM; $\alpha 1\beta 2$ (N265M) $\gamma 2$: 8 μM; $\alpha 1\beta 2$ (M286W) $\gamma 2$: 1 μM).

Propofol

Propofol is a widely used intravenous general anaesthetic agent. In HEK 293 cells expressing the $\alpha 1\beta 2\gamma 2$ receptor, 10 μM propofol potentiated the GABA-induced chloride current by 100.7 ± 17% (n = 16). In cells expressing the $\alpha 1\beta 2$ (N265M) $\gamma 2$ receptor, this potentiation amounted to 43.5 ± 10.1% (n = 10) and thus was significantly smaller (p < 0.05). Similarly, in cells expressing $\alpha 1\beta 2$ (M286W) $\gamma 2$ receptor the potentiation was 48.4 ± 13.2% (n = 16), and thus also significantly smaller than in wild type (p < 0.05). Thus, the $\beta 2$ (N265M) mutation and the $\beta 2$ (M286W) mutation significantly reduced the potentiation of GABA-induced chloride currents by propofol (Fig. 2).

Etomidate

Etomidate is also a clinically used intravenous anaesthetic. In cells expressing $\alpha 1\beta 2\gamma 2$ receptors, 10 μM etomidate potentiated the GABA-induced chloride current by 372 ± 103.4% (n = 10). The potentiation at the $\alpha 1\beta 2$ (N265M) $\gamma 2$ receptor was significantly smaller (83.7 ± 23.5%; n = 13; p < 0.05), as was the potentiation at the $\alpha 1\beta 2$ (M286W) $\gamma 2$ receptor (87.4 ± 34.1%; n = 11; p < 0.05). Thus, both the $\beta 2$ (N265M) mutation and the $\beta 2$ (M286W) mutation significantly reduce the potentiation of GABA-induced chloride currents by etomidate (Fig. 2).

Alphaxalone

5 μM of the neuroactive steroid anaesthetic alphaxalone potentiated the GABA-induced current in cells expressing the $\alpha 1\beta 2\gamma 2$ receptor by 327 ± 59.4% (n = 17), in cells expression the $\alpha 1\beta 2$ (N265M) $\gamma 2$ receptor 346.5 ± 97.4% (n = 11) and in cells expressing the $\alpha 1\beta 2$ (M286W) $\gamma 2$




Figure 2
 Modulatory action of intravenous general anesthetic at $\alpha_1\beta_2\gamma_2$ GABA_A receptors. (a) Single traces of the effects of the intravenous anaesthetics propofol (Prop), etomidate (Etom) and alphaxalone (Alphax) on GABA-evoked chloride currents. (b) The potentiation of the GABA-evoked chloride currents is expressed relative to the control currents at the given GABA concentration (means \pm standard error, n = 10–17; *p < 0.05; Student's t-test).

receptor by $201.6 \pm 45.6\%$ ($n = 14$). The values obtained for the mutant receptors were not significantly different from wild type. Thus, both mutations have no effect on the potentiation of GABA-induced chloride currents by alphaxalone (Fig. 2).

Enflurane

Enflurane is a clinically used volatile general anaesthetic. 1 mM enflurane potentiated GABA-induced currents by $119.4 \pm 23\%$ ($n = 8$) in cells expressing the $\alpha 1\beta 2\gamma 2$ receptor, $31.7 \pm 10\%$ ($n = 13$) in cells expressing the $\alpha 1\beta 2(N265M)\gamma 2$ receptor and $4.8 \pm 2.1\%$ ($n = 11$) in cells expressing the $\alpha 1\beta 2(M286W)\gamma 2$ receptor (Fig. 3). The values for both mutant receptors are significantly different from wild type ($p < 0.01$). Thus, both mutations significantly reduce the potentiation of GABA-induced chloride currents by enflurane.

Direct activation of GABA_A receptors by general anaesthetics

At concentrations usually higher than those required for potentiation of GABA-induced chloride currents, propofol, etomidate and alphaxalone display a direct agonistic action on GABA_A receptors. The direct actions of these compounds were compared to the maximal GABA current at the respective receptor, which was determined separately.

Propofol

50 μ M propofol induced a chloride current amounting to $20 \pm 7\%$ ($n = 12$) of the maximal GABA-induced current, which was determined separately, in cells expressing the $\alpha 1\beta 2\gamma 2$ receptor (Fig. 4). In contrast, in cells expressing the $\alpha 1\beta 2(N265M)\gamma 2$ or $\alpha 1\beta 2(M286W)\gamma 2$ receptors, 50 μ M propofol induced chloride currents amounting to $0.7\% \pm 0.3\%$ ($n = 17$) and $2.0 \pm 0.8\%$ ($n = 10$), respectively, of the maximal GABA-induced current, thus being significantly smaller ($p < 0.05$) compared to wild type (Fig. 4). Thus, both mutations almost abolish the direct action of propofol on the $\alpha 1\beta 2\gamma 2$ receptor.

Etomidate

10 μ M Etomidate induced a chloride current amounting to $33 \pm 11\%$ ($n = 13$) of the maximal GABA-induced current in cells expressing the $\alpha 1\beta 2\gamma 2$ receptor (Fig. 4). In cells expressing $\alpha 1\beta 2(N265M)\gamma 2$ or $\alpha 1\beta 2(M286W)\gamma 2$ receptors, this direct effect was significantly reduced to $0.4 \pm 0.2\%$ ($n = 19$; $p < 0.05$) and $2.1 \pm 0.5\%$ ($n = 10$); $p < 0.05$), respectively (Fig. 4). Thus, the two point mutations abolish the direct action of etomidate on the $\alpha 1\beta 2\gamma 2$ receptor.

Alphaxalone

10 μ M Alphaxalone induced a chloride current amounting to $49.8\% \pm 18\%$ ($n = 12$) of the maximal GABA-

induced chloride current in cells expressing the $\alpha 1\beta 2\gamma 2$ receptor (Fig. 4). Whereas the alphaxalone-induced current is significantly reduced in cells expressing the $\alpha 1\beta 2(N265M)\gamma 2$ receptor ($5.6 \pm 1.2\%$; $n = 19$, $p < 0.05$), it was non-significantly decreased in cells expressing the $\alpha 1\beta 2(M286W)\gamma 2$ receptor ($31.1 \pm 9.1\%$; $n = 9$) (Fig. 4). Thus, while the $\beta 2(N265M)$ mutation significantly reduces the extent of direct activation by alphaxalone, the $\beta 2(M286W)$ mutation had no effect.


Discussion

In the present study we assessed the phenotypic consequences of two point mutations in the second (TM2) and third (TM3) transmembrane domains of the GABA_A receptor $\beta 2$ subunit, $\beta 2(N265M)$ and $\beta 2(M286W)$, respectively, with respect to GABA sensitivity and the action of general anaesthetic agents on the most abundant GABA_A receptor subtype in the central nervous system, $\alpha 1\beta 2\gamma 2$. This is particularly important for potential future analysis of these mutations in knock-in point-mutated mice.

At amino acid position 265 of the $\beta 2$ subunit, an asparagine has been replaced by a methionine, which is the corresponding residue in the etomidate-insensitive *Drosophila rdl* receptor. The $\beta 3(N265M)$ mutation indeed largely abolished the direct and modulatory actions of etomidate and propofol on $\alpha 6\beta 3\gamma 2$ receptors [3,13]. In $\alpha 2\beta 1(S265I)$ receptors, the potentiation of the GABA current by enflurane was inhibited by less than 50%, however, the potentiation by isoflurane was completely abolished, while the potentiating action of propofol, etomidate, methohexital and alphaxalone was not changed [4,6]. In the same study, the direct action of propofol and etomidate, but not methohexital was shown to be impaired by this mutation [6]. Recently, we showed that the $\beta 3(N265M)$ mutation, when studied in the $\alpha 2\beta 3(N265M)\gamma 2$ receptor, almost abolished the modulatory actions of propofol and etomidate, but not alphaxalone, and reduced the modulatory action of enflurane by ca. 80% [14]. Likewise, the direct actions of propofol and etomidate, but not alphaxalone were almost abolished [14].

In the present study, we find that the $\beta 2(N265M)$ mutation decreases the sensitivity of the $\alpha 1\beta 2\gamma 2$ receptor for GABA, with an increase of the EC_{50} value from $5.9 \pm 0.5 \mu$ M to $20 \pm 2.2 \mu$ M. Harrison and colleagues [15] also reported a shift of the GABA dose-response curve to the right by this mutation. We show that this mutation significantly reduces the modulatory action of propofol, etomidate and enflurane, but not alphaxalone, similar to what we previously reported for the $\alpha 2\beta 3\gamma 2$ receptor [14]. Nishikawa et al. [17] recently observed that the modulatory action of the volatile anaesthetics isoflurane, sevoflurane and desflurane at $\alpha 1\beta 2(N265M)\gamma 2$ receptors is also

a



b




Figure 3


Modulatory action of the volatile general anaesthetic enflurane at $\alpha_1\beta_2\gamma_2$ GABA_A receptors. (a) Histogram of the modulation of GABA-induced chloride currents by enflurane (means \pm standard error, n = 8–13; **p < 0.01; Student's t-test). (b) Single traces showing the effects of the volatile anaesthetic enflurane (enflur) on GABA-evoked chloride currents.

reduced. In $\alpha_1\beta_2(\text{N265M})\gamma_2$ receptors, the direct action of etomidate and propofol was completely abolished, which is in line with the results obtained on the $\alpha_2\beta_3(\text{N265M})\gamma_2$ receptor, while the direct action of alphaxalone was significantly reduced, in contrast to our results obtained on the $\alpha_2\beta_3(\text{N265M})\gamma_2$ receptor [14]. Thus, with the notable exception of the direct action of alphaxalone, similar results were obtained concerning the effect on the N265M mutation in the β_2 and β_3 subunits.

At amino acid position 286 of the β_2 subunit, a methionine was replaced by a tryptophane. Tryptophan is the

homologous residue in the GABA_A receptor ρ_1 subunit, which is insensitive for general anaesthetics, e.g., enflurane [4]. When the $\beta_1(\text{M286W})$ mutation was studied in $\alpha_1\beta_1$ receptors, the modulatory action of enflurane was abolished [4]. When this mutation was introduced into $\alpha_2\beta_1$ receptors, the modulatory action of isoflurane and propofol were abolished and the modulatory action of methohexital reduced, but the modulatory actions of etomidate and alphaxalone were unaffected by the mutation [6]. In contrast, the direct action of etomidate was decreased, but the direct action of propofol and methohexital were not changed [6]. The same group also found

a



b




Figure 4

Direct activation of $\alpha_1\beta_2\gamma_2$ GABA_A receptors by intravenous general anesthetics. (a) Bar histogram of the direct activation of GABA_A receptor-mediated chloride currents by propofol, etomidate and alphaxalone. Data points represent means \pm standard error, n = 9–19; *p < 0.05; Student's t-test). (b) Selected traces showing representative whole-cell chloride currents activated by propofol, etomidate and alphaxalone.

that the GABA sensitivity was unchanged compared to wild type in the $\alpha 2\beta 1$ (M286W) receptor as well as in the $\alpha 1\beta 2$ (M286W) $\gamma 2$ receptor [6,16]. In the present study, however, we find that the EC_{50} of the $\alpha 1\beta 2$ (M286W) $\gamma 2$ receptor is reduced approximately three-fold. Our findings are in line with our observation that the corresponding $\beta 3$ (M286W) mutation also leads to a similar reduction of the EC_{50} in $\alpha 2\beta 3$ (M286W) $\gamma 2$ receptors. The source of the discrepancies between the results reported by the two groups are not clear.

For etomidate, Harrison and colleagues reported no significant change of the modulatory action on $\alpha 2\beta 1$ (M286W) receptors compared to wild type [6], but a significant reduction of the modulatory action on the $\alpha 1\beta 2$ (M286W) $\gamma 2$ receptor compared to wild type (from $237 \pm 45\%$ ($n = 6$) in wild type to $162 \pm 11\%$ ($n = 5$)) [16]. With the same concentration of etomidate (10 μ M), we observed a decrease of the modulatory action from $372 \pm 103.4\%$ ($n = 10$) in wild type to $87.4 \pm 34.1\%$ ($n = 11$; $p < 0.05$). In our study, the $\beta 2$ (M286W) mutation had no significant effect on the modulatory action of alphaxalone. This is in line with the observation that the modulatory effect of alphaxalone is indistinguishable from wild type in $\alpha 2\beta 1$ (M286W) and $\alpha 1\beta 2$ (M286W) $\gamma 2$ receptors [6,16] as well as $\alpha 2\beta 3$ (M286W) $\gamma 2$ receptors [14]. Our finding that the enflurane action is almost completely abolished in the $\alpha 1\beta 2$ (M286W) $\gamma 2$ receptor also corresponds with our previous findings on the $\alpha 2\beta 3$ (M286W) $\gamma 2$ receptor [14]. Whereas the direct action of propofol on the $\alpha 2\beta 1$ (M286W) receptor has been reported to be indistinguishable from wild type, the direct action of etomidate was reported to be significantly reduced in the $\alpha 2\beta 1$ (M286W) receptor [6]. In our study, however, using the same concentration of propofol (50 μ M), we found a significant decrease of the direct activation of the $\alpha 1\beta 2$ (M286W) $\gamma 2$ receptor compared to wild type. The direct action of etomidate was also significantly reduced. A reduction of the direct action of propofol on the $\alpha 1\beta 2$ (M286W) $\gamma 2$ receptor was also reported by [16]. In contrast, we previously reported that the direct action of propofol is indistinguishable from wild type in the $\alpha 2\beta 3$ (M286W) $\gamma 2$ receptor [14]. These results are consistent with the notion that the M286W mutation has different phenotypic consequences in GABA_A receptors with different $\alpha\beta\gamma$ subunit combinations.

A further subtype-specific difference in the direct action of anaesthetics was observed for the neuroactive steroid alphaxalone. Whereas the direct effect of alphaxalone on the $\alpha 2\beta 3$ (M286W) $\gamma 2$ receptor was significantly higher compared to wild type, the direct effect of alphaxalone was indistinguishable from wild type in the $\alpha 1\beta 2$ (M286W) $\gamma 2$ receptor.

In conclusion, this study demonstrates the consequences of the $\beta 2$ (N265M) and $\beta 2$ (M286W) mutations on anaesthetic actions on the most abundant GABA_A receptor subtype in the central nervous system, $\alpha 1\beta 2\gamma 2$, indicating that these mutations are suitable to study the relevance of this GABA_A receptor for general anaesthesia in mice. At the same time, they demonstrate that the phenotypic consequences of mutations at homologous positions of β subunits can vary between receptor subtypes and that extrapolations should only be done with caution.

Methods

Experimental procedures were similar to those described previously [14]. Rat $\alpha 1$, $\beta 2$, and $\gamma 2_{\text{short}}$ subunit cDNAs in the expression vector pBC12/CMV [9] were used in this study. In the $\beta 2$ subunit, the asparagine residue at position 265 was changed to a methionine residue [$\beta 2$ (N265M)] and, independently, the methionine residue at position 286 was changed to a tryptophane residue [$\beta 2$ (M286W)] using the QuikChange[®] site-directed mutagenesis kit (Stratagene, La Jolla, California, USA) with complementary oligonucleotides spanning the mutations. For the [$\beta 2$ (N265M)] mutation, oligonucleotides SL-3:

5'-GACGATGACCACAATCATGACCCATCTCCGGGA-GACTC-3' and SL-4:

5'-GAGTCTCCCGGAGATGGGTCATGATTGTGGT-CATCGTC-3' were used (mutated codon underlined). For the [$\beta 2$ (M286W)] mutation, oligos SL-5:

5'-GCCATTGACATGTACCTA TGGGGGTGCTTTGTCTTT-GTC-3' and SL-6:

5'-ACAAAGACAAAGCACCCCATAGGTACATGTCAAT-GGC-3' were used (mutated codon underlined). The numbering of amino acids is based on the mature protein after cleavage of the signal peptide.

Human embryonic kidney cells 293 (HEK 293) were grown in Dulbecco's modified Eagle medium (DMEM, Gibco, Invitrogen, Basel, Switzerland) supplemented with 5% heat inactivated fetal calf serum (FCS, Gibco, Invitrogen, Basel, Switzerland), 100 U/ml penicillin and 100 mg/ml streptomycin (both from Gibco, Invitrogen, Basel, Switzerland). Cells were transiently transfected using the calcium phosphate precipitation technique.

The patch-clamp technique in the whole-cell configuration was used to record GABA-induced Cl⁻ currents. The membrane potential was held at -60 mV. The current signals were amplified with an Axopatch-1D amplifier (Axon Instruments, Inc., Foster City, CA, USA), filtered by a 1 KHz four-pole Bessel low-pass filter. The analysis of data was performed using the pClamp data acquisition program set (pClamp 8.0, Axon Instruments) and FigP (Bio-soft, Cambridge, UK). The GABA dose-response curves were obtained by applying 5-sec pulses of GABA every 1.5

min to the patch-clamped HEK 293 cells. The maximum current amplitudes from individual cells were first fitted separately using the equation $I/I_{\max} = 1 / (1 + (EC_{50}/[GABA])^{\text{Hill}})$, where I is GABA-evoked current, I_{\max} is the maximum of the fit, EC_{50} is the GABA concentration evoking the half-maximal response, and Hill is the Hill coefficient. The individual dose-response curves were then normalized to I_{\max} , and the data replotted using the mean values for each concentration.

Drug application

GABA was applied in the presence or absence of drugs to the patch-clamped cell for 5 sec every 1.5 min using a multibarrelled microapplicator pipette constructed from seven concentrically arranged glass tubes ending in a common tip. Air-tight syringes, containing the solutions, were connected to the microapplicator via Teflon tubes, in order to avoid loss of the anaesthetics due to evaporation or sticking to the tubes. Six of the tubes were used for drug delivery, and the seventh tube at the center provided slow aspiration to prevent accumulation of drugs in the common tip and leakage from the inactive barrels. To allow a rapid shut-off of the drug application, a sucking pipette was placed in front of the tip of the drug-applicator, in order that the tested cell was positioned between the applicator and the suction. In this way, the solution coming from the application bathed the cell and was directly and rapidly sucked out by the suction.

Solutions and drugs

The recording pipettes were filled with an intracellular saline solution containing 120 mM CsCl, 20 mM TEACl, 1 mM $CaCl_2$, 2 mM $MgCl_2$, 11 mM EGTA, 10 mM HEPES, adjusted to pH 7.2 with CsOH. The cells, placed in a petri-dish fitting into the recording chamber, were continuously superfused with a bath solution using a second applicator. The bath solution contained 157 mM NaCl, 5.4 mM KCl, 1.8 mM $CaCl_2$, 1 mM $MgCl_2$ and 5 mM HEPES, adjusted to pH 7.4 with NaOH. The experiments were performed at room temperature. GABA was from Sigma (St. Louis, Mo, USA), etomidate from Janssen Pharmaceutica (Beerse, Belgium). Propofol from Aldrich (Buchs, Switzerland), alphaxalone from Sigma (Buchs, Switzerland) and enflurane from Abbott Laboratories (Cham/ Zug, Switzerland). GABA was dissolved in water and used at concentrations of 3 μ M for $\alpha_1\beta_2\gamma_2$ receptors, 8 μ M $\alpha_1\beta_2(N265M)\gamma_2$ receptors and of 1 μ M for $\alpha_1\beta_2(M286W)\gamma_2$ receptors, which correspond to EC_{15} for all receptors. Stock solutions of the test compounds were prepared in 100 % DMSO and diluted 1000-fold before use. During the experiments, the final concentrations of DMSO in the bath solutions were not higher than 0.1 %, which had no effect on GABA responses. The volatile enflurane was dissolved in the external solution. Fresh solutions were prepared every hour. We expect only a small loss of enflurane

of ca. 10% to 15%, which would affect recordings from wild type and mutant receptors in the same way.

Authors' contributions

R.S. and K.K. performed and analyzed the electrophysiological experiments and drafted the manuscript, S.L. performed the molecular biology work, and U.R. directed the study and drafted and finalized the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by the Swiss National Science Foundation.

References

1. Krasowski MD and Harrison NL: **General anesthetic actions on ligand-gated ion channels.** *Cell Mol Life Sci* 1999, **55**:1278-1303.
2. Yamakura T, Bertaccini E, Trudell JR and Harris RA: **Anesthetics and ion channels: molecular models and sites of action.** *Ann Rev Pharmacol Toxicol* 2001, **41**:23-251.
3. Belelli D, Lambert JJ, Peters JA, Wafford KA and Whiting PJ: **The interaction of the general anesthetic etomidate with the γ -aminobutyric acid type A receptor is influenced by a single amino acid.** *Proc Natl Acad Sci USA* 1997, **94**:11031-11036.
4. Mihic SJ, Ye Q, Wick MJ, Koltchine VV, Krasowski MD, Finn SE, Mascia MP, Valenzuela CF, Hanson KK, Greenblatt EG, Harris RA and Harrison NL: **Sites of alcohol and volatile anesthetic action on $GABA_A$ and glycine receptors.** *Nature* 1997, **389**:385-389.
5. Moody EJ, Knauer C, Granja R, Strakhova M and Skolnick P: **Distinct loci mediate the direct and indirect actions of the anesthetic etomidate at $GABA_A$ receptors.** *J Neurochem* 1997, **69**:1310-1313.
6. Krasowski MD, Koltchine VV, Rick CE, Ye Q, Finn SE and Harrison NL: **Propofol and other intravenous anesthetics have sites of action on the γ -aminobutyric acid type A receptor distinct from that for isoflurane.** *Mol Pharmacol* 1998, **53**:530-538.
7. Scheller M and Forman SA: **The γ subunit determines whether anesthetic-induced leftward shift is altered by a mutation at $\alpha 1S270$ in $\alpha 1\beta 2\gamma 2L$ $GABA_A$ receptors.** *Anesthesiology* 2001, **95**:123-131.
8. McKernan RM and Whiting PJ: **What $GABA_A$ -receptor subtypes really occur in the brain?** *Trends Neurosci* 1996, **19**:139-143.
9. Benson JA, Löw K, Keist R, Möhler H and Rudolph U: **Pharmacology of recombinant γ -aminobutyric acid_A receptors rendered diazepam-insensitive by point-mutated α subunits.** *FEBS Lett* 1998, **431**:400-404.
10. Ebert B, Wafford KA, Whiting PJ, Krosgaard-Larsen P and Kemp J: **Molecular pharmacology of γ -aminobutyric acid type A receptor agonists and partial agonists in oocytes injected with different α , β , and γ subunit combinations.** *Mol Pharmacol* 1994, **46**:957-963.
11. Nagata K, Hamilton BJ, Carter DB and Narahashi T: **Selective effects of dieldrin on the $GABA_A$ receptor channel subunits expressed in human embryonic kidney cells.** *Brain Res* 1994, **645**:19-26.
12. Ducic I, Caruncho HJ, Zhu WJ, Vicini S and Costa E: **γ -aminobutyric acid gating of Cl⁻ channels in recombinant $GABA_A$ receptors.** *J Pharmacol Exp Ther* 1995, **272**:438-445.
13. Pistis M, Belelli D, McGurk K, Peters JA and Lambert JJ: **Complementary regulation of anaesthetic activation of human ($\alpha 6\beta 3\gamma 2L$) and drosophila (RDL) $GABA_A$ receptors by a single amino acid residue.** *J Physiol* 1999, **515**:3-18.
14. Siegwart R, Jurd R and Rudolph U: **Molecular determinants for the action of general anesthetics at recombinant $\alpha 2\beta 3\gamma 2$ γ -aminobutyric acid_A receptors.** *J Neurochem* 2002, **80**:140-148.
15. Nishikawa K, Jenkins A, Paraskevakis I and Harrison NL: **Volatile anesthetic actions of the $GABA_A$ receptors: contrasting effects of $\alpha 1(S270)$ and $\beta 2(N265M)$ mutations.** *Neuropharmacology* 2002, **42**:337-345.
16. Krasowski MD, Nishikawa K, Nikolaeva N, Lin A and Harrison NL: **Methionine 286 in transmembrane domain 3 of the $GABA_A$ receptor β subunit controls a binding cavity for propofol and**

other alkylphenol general anesthetics. *Neuropharmacology* 2001, **41**:952-964.

17. Nishikawa K and Harrison NL: **The action of sevoflurane and desflurane on the γ -aminobutyric acid receptor type A: effects of TM2 mutations in α and β subunits.** *Anesthesiology* 2003, **99**:678-684.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

